linjc16/ctgov huggingface dataset:
Double Carbapenem as Rescue Strategy for the Treatment of Carbapenemase-Producing Klebsiella Pneumoniae Infections

Study Overview
=================
Brief Summary
-----------------
An observational two-center case-control study exploring the clinical impact of double-carbapenem use in a population of critically il patients with severe carbapenem-resistant Klebsiella pneumoniae infection

Official Title
-----------------
Double Carbapenem as Rescue Strategy for the Treatment of Severe Carbapenemase-Producing Klebsiella Pneumoniae Infections: A Two-Center Matched Case-Control Study

Conditions
-----------------
Carbapenem, Klebsiella Pneumonia

Intervention / Treatment
-----------------
* Other: none intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 years; ICU admission between November 2012 and December 2015; documented CR-Kp invasive infection; targeted antibiotic therapy lasting ≥ 72 hours Exclusion Criteria Klebsiella infection, susceptible to carbapenems Duration of antimicrobial therapy less than 72 hours Data not completely available from the electronically medical chart

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Double Carbapenem Group<br>Patients underwent Double carbapenem treatment | Other: none intervention<br>* none intervention<br>|
| Standard Treatment Group<br>Patients who were not treated with the double carbapenem | Other: none intervention<br>* none intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28-day mortality | mortality after 28 day from infection | 28 day |
Comparison of Different Video Laryngoscopes in < 1 Year Old Undergoing Neurosurgical Operations: a Prospective Randomized Study

Study Overview
=================
Brief Summary
-----------------
İntubation of pediatric patients is a challenging problem. Video laryngoscopes increased the intubation success rate. We want to compare different video laryngoscopes in this field.

Detailed Description
-----------------
Aim:İntubation of pediatric patients is a challenging problem. Video laryngoscopes increased the intubation success rate. We want to compare different video laryngoscopes in this field. methods: We enroll total 50 patients < 1 year old undergoing neurosurgery. We compared the intubation times, success rates and minor complications of Airtraq and c-mac video laryngoscopes in these pediatric patients undergoing neurosurgery.

Official Title
-----------------
Comparison of Airtraq and C-mac in Pediatric Patients Under 1 Year Old

Conditions
-----------------
Intubation;Difficult

Intervention / Treatment
-----------------
* Device: airtraq
* Device: c-mac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: < 1 years old undergoing neurosurgery ASA 1-2 Exclusion Criteria: > 1 year old asa 3-4 emergency

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: intubation time airtraq<br>intubation time of Airtraq | Device: airtraq<br>* device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords<br>* Other names: videolaryngoscope;|
| Active Comparator: intubation time of c-mac<br>intubation time of c-mac | Device: c-mac<br>* device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords<br>* Other names: videolaryngoscope;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intubation time | device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords | 30 seconds | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
videolaryngoscope, airtraq, c-mac, infant, intubatioon
Evaluation of Alternative Exercise Treatments on Weight Loss in Overweight Women.

Study Overview
=================
Brief Summary
-----------------
The purpose is to examine the additional effect of either yoga or resistance exercise on weight loss weight combined with a standard behavioral weight loss intervention.

Official Title
-----------------
Evaluation of Alternative Exercise Treatments on Weight Loss in Overweight Women.

Conditions
-----------------
Obesity, Weight Loss

Intervention / Treatment
-----------------
* Behavioral: behavioral weight loss


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female 25-55 years of age BMI = 25-35 kg/m2 Ability to provide informed consent. Ability to provide consent from their personal physician to participate in this study. Exclusion Criteria: Participation in regular exercise (aerobic, yoga or resistance exercise) for > 20 minutes per day on > 2 days per week for the last 3 months. (This study is designed to recruit relatively sedentary adults.) Currently being treated for psychological disorders/conditions and/or currently taking psychotropic medication. Diabetes, hypothyroidism, or other medical conditions which would affect energy metabolism. Women who are currently pregnant, pregnant within the previous six months, or planning on becoming pregnant within the next 12 months. (Pregnancy during initial screening will be based on self-report and will be included on the detailed medical history that is completed by subjects. However, pregnancy status will also be verified by the pregnancy test that is required for the baseline, 6 and 12 month DEXA). Non-medicated resting systolic blood pressure >160 mmHg or non-medicated resting diastolic blood pressure >100 mmHg, or taking medication that would affect blood pressure. Taking medication that would affect resting heart rate or the heart rate response during exercise (e.g., beta blockade). Arrhythmia on resting or exercise electrocardiogram that would indicate that vigorous exercise was contraindicated. History of myocardial infarction or valvular disease. History of orthopedic complications that would prevent optimal participation in the exercise component (e.g., heel spurs, severe arthritis).

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: behavioral weight loss|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight loss |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fitness |  |  | 
| physical activity |  |  | 
| dietary intake |  |  | 
| mediators |  |  |
Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

Study Overview
=================
Brief Summary
-----------------
To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.

Official Title
-----------------
Double-blind, Placebo-controlled, Randomized Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

Conditions
-----------------
Carcinoma, Hepatocellular

Intervention / Treatment
-----------------
* Drug: Thalidomide(Thado)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with measurable, metastatic or locally advanced hepatocellular carcinoma The diagnosis of HCC should be established either by cyto/histology Patients must be > 20 years of age. ECOG score < 2. Signed informed consent. Female patients at child-bearing age must have negative pregnancy test. Exclusion Criteria: Patients with other systemic diseases which require concurrent usage of glucocorticosteroid or immunosuppressant agent(s) are not eligible. Patients with advanced second primary malignancy are not eligible. Patients with active infection are not eligible. Patients with pregnancy or breast-feeding are not eligible. Patients with brain metastases are not eligible.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Thalidomide(Thado)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Phase III, Hepatocellular Carcinoma
Endophthalmitis Cultures

Study Overview
=================
Brief Summary
-----------------
The intent of this surveillance study will be to obtain written permission from patients with bacterial endophthalmitis in order to compare sterilization rates of their cultured bacterial isolates to standard therapy (vancomycin and ceftazidime) versus combination therapy with vancomycin, ceftazidime, and moxifloxacin. Research hypothesis: Cultured bacterial isolates will demonstrate faster in vitro sterilization rates with combination treatment (vancomycin, ceftazidime, and moxifloxacin) compared to standard therapy with vancomycin and ceftazidime. Longitudinal analysis of resistance patterns of cultured isolates will show increasing rates of multi-antibiotic resistance.

Detailed Description
-----------------
Adult patients over 18 years of age presenting with endophthalmitis and able to sign consent.

Official Title
-----------------
Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study

Conditions
-----------------
Endophthalmitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all adult patients age 18 or greater presenting with bacterial endophthalmitis to the Vanderbilt Eye Institute and who grow positive cultures Exclusion Criteria: Patients < 18 years of age or those patients without positive cultures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endophthalmitis cultures<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Esthesioneuroblastoma: Outcomes After Treatment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect and organize data into a repository to gather relevant information for future research from patients diagnosed with a rare malignant sinonasal cancer called esthesioneuroblastoma (ENB) and are scheduled to undergo endonasal skull base surgery. Data being collected includes surgical data, demographics, disease presentation, MRI, CT, PET imaging, and post-operative assessments including pathology tests. After surgery, the investigators will collect chemotherapy and radiation data. Participants will also complete quality of life questionnaires at their follow-up visits.

Official Title
-----------------
Esthesioneuroblastoma: Outcomes After Treatment

Conditions
-----------------
Esthesioneuroblastoma, Olfactory

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the age of 10-80 years Diagnosed with esthesioneuroblastoma Exclusion Criteria: Refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Life | Anterior Skull Base (ASB); Skull Base Inventory (SBI); Multidimensional Disease Specific Inventory MDS; ASB-Nasal 12; Sino-Nasal Outcome Test (SNOT-20) | up to 120 months after treatment | 
| Progression-free survival and overall survival | Kaplan-Meier survival curves | Up to 120 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with intraoperative complications |  | up to 120 months | 
| Number of participants with postoperative complications |  | up to 120 months | 
| Length of Hospital Stay |  | up to 120 months | 
| Time spent in operating room |  | up to 120 months | 
| MRI imaging evidence of resection |  | up to 120 months | 
| Surgical Technique |  | up to 120 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Esthesioneuroblastoma, Tumor, Skull Base Surgery, Sinonasal Cancer
Angiotensin Converting Enzyme Gene Polymorphism in Children With Idiopathic Nephrotic Syndrome

Study Overview
=================
Brief Summary
-----------------
Aims This study was conducted to examine the association between the ACE insertion/deletion (I/D) genotype distribution in children with idiopathic nephrotic syndrome and the response to steroid therapy. Patients and Methods The patients with idiopathic nephrotic syndrome were divided into 2 groups according to their clinical response to steroid: SS group including infrequent and frequent relapsers and non-SS group including steroid resistant (SR) and steroid dependent (SD) patients. Children without previous renal diseases and negative proteinuria were enrolled as control group in genetic study. The genotypes for ACE gene I/D polymorphism including DD, ID and II were analyzed by the newly developed automatic denaturing high performance liquid chromatography system (DHPLC).

Conditions
-----------------
Nephrotic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Total 59 children diagnosed as nephrotic syndrome at the age of 1 to 10 year-old were recruited in this study. These children with nephrotic syndrome were under follow-up at the Pediatric Nephrology Clinic in National Taiwan University Hospital. In addition, children without previous renal diseases and negative proteinuria were enrolled as control group in genetic study.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.

Official Title
-----------------
Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Conditions
-----------------
Infectious Keratitis

Intervention / Treatment
-----------------
* Other: Ultraviolet-A and riboflavin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must be 18 years of age or older. Ability to provide written informed consent. Likely to complete all study visits. Subjects must have one eye that with a diagnosis of infectious keratitis. Exclusion Criteria: A corneal perforation. Descemetocele. Pregnancy or breastfeeding. Active Herpes corneal disease. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ultraviolet-A and riboflavin<br> | Other: Ultraviolet-A and riboflavin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resolution of Signs and Symptoms of Infectious Keratitis |  | Subjects will be followed until resolution of signs and symptoms, an expected average of 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infectious Keratitis
Comparison of MR Enteroclysis and MRI With Per Oral Contrast Using a 6 % Mannitol Solution.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare MRI enteroclysis with MRI of the small bowel with a per oral 6%mannitol solution.Our hypothesis is that the peroral technique preform the same way as MRI Enteroclysis.

Official Title
-----------------
MRI of the Small Bowel. Comparison of Different Techniques and Contrast.

Conditions
-----------------
Magnetic Resonance Imaging, Intestine Small, Crohn Disease.

Intervention / Treatment
-----------------
* Procedure: MRI of the small bowel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: above 18 years known Crohns disease or strong suspicion. need of a small bowel examination Exclusion Criteria: pregnant electrolyte disturbances. Any MRI contraindications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: MRI of the small bowel|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
To Evaluate the Role of Lung Ultrasonography for Detection of Atlelectasis in Robot Assisted Laproscopic Pelvic Sugeries

Study Overview
=================
Brief Summary
-----------------
Pre op ultrasound with chest auscultation and arterial blood gas, after extubation ultrasound with chest auscultation and blood gas, 12hrs chest auscultation with ultasaound, 24 hrs chest auscultation and ultrasound to see atelectasis

Detailed Description
-----------------
Pre op ultrasound with chest auscultation and arterial blood gas, after extubation ultrasound with chest auscultation and blood gas, 12hrs chest auscultation with ultasaound, 24 hrs chest auscultation and ultrasound to see atelectasis inclusion criteria: age 18 to 70 yrs age ASA I and II robot assisted pelvic surgeries in steep trendelenburg position exclusion criteria: cardiac disese severe obstructive and restrictive disease upper airways infection ASAIII and IV

Official Title
-----------------
TO EVALUATE THE ROLE OF LUNG ULTRASONOGRAPHY FOR DETECTION OF ATELECTASIS IN ADULTS UNDERGOING ROBOT ASSISTED LAPAROSCOPIC PELVIC SURGERIES

Conditions
-----------------
to Detect the Incidence of Atelectasis

Intervention / Treatment
-----------------
* Other: lung ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA Iand II age 18-70 yrs robot assisted pelvis surgeries Exclusion Criteria: ASA II and IV cardiac and lung disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: lung ultrasound|lung ultrasound and blood gas|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of atelectasis | incidence of atelectasis in adults after extubation undergoing robot assisted pelvic laproscopic surgery in steep trendelenberg position using ultrasound | 24hrs | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk factor identification | risk factor identification of post operative atelectasis | 24hrs |